Publikation: Helical Tomotherapy of Lymph Node-negative Early-stage Breast Cancer After Breast-conserving Surgery : Long-term Results
Dateien
Datum
Autor:innen
Herausgeber:innen
ISSN der Zeitschrift
Electronic ISSN
ISBN
Bibliografische Daten
Verlag
Schriftenreihe
Auflagebezeichnung
DOI (zitierfähiger Link)
Internationale Patentnummer
Angaben zur Forschungsförderung
Projekt
Open Access-Veröffentlichung
Sammlungen
Core Facility der Universität Konstanz
Titel in einer weiteren Sprache
Publikationstyp
Publikationsstatus
Erschienen in
Zusammenfassung
Background/Aim: Adjuvant radiotherapy is an integral part of the interdisciplinary curative treatment of breast cancer. We aimed to examine the long-term clinical results of helical tomotherapy in female patients with local restricted, lymph node negative breast cancer after breast-conserving surgery.
Patients and Methods: In this single-centre analysis, 219 female patients with early-stage breast cancer (T1/2) and no lymph node metastasis (N0) following breast-conserving surgery and sentinel-node biopsy were treated with adjuvant fractionated whole breast radiation therapy using helical tomotherapy. When boost irradiation was indicated, it was administered sequentially or using the simultaneous-integrated boost technique. Local control (LC), metastasis and survival rates, acute toxicity, late toxicity, and secondary malignancy rates were analysed retrospectively.
Results: The mean follow-up time was 71 months. The 5- and 8-year overall survival (OS) rates were 97.7% and 92.1%, respectively. The 5- and 8-year LC rates were 99.5% and 98.2%, while the 5- and 8-year metastasis-free survival (MFS) rates of 97.4% and 94.3%, respectively. Patients with G3 grading or negative hormone receptor status did not show significantly different results. Acute erythema occurred in 79% (grade 0-2) and 21% (grade 3) of the patients. Lymphedema of the ipsilateral arm and pneumonitis occurred in 6.4% and 1.8% of the treated patients. None of the patients developed >grade 3 toxicities during follow-up, while 1.8% developed a secondary malignancy during follow-up.
Conclusion: Helical tomotherapy showed excellent long-term results and low toxicity rates. The incidence rates of secondary malignancy were relatively low and correlated with pre-existing data on radiotherapy, suggesting wider implementation of helical tomotherapy in adjuvant radiotherapy for breast cancer patients.
Zusammenfassung in einer weiteren Sprache
Fachgebiet (DDC)
Schlagwörter
Konferenz
Rezension
Zitieren
ISO 690
ZWICKER, Felix, Rudolf KLEPPER, Henrik HAUSWALD, Sebastian HÖFEL, Luis RAETHER , Peter E. HUBER, Juergen DEBUS, Michael SCHEMPP, 2023. Helical Tomotherapy of Lymph Node-negative Early-stage Breast Cancer After Breast-conserving Surgery : Long-term Results. In: Anticancer Research. International Institute of Anticancer Research. 2023, 43(5), pp. 2041-2053. ISSN 0250-7005. eISSN 1791-7530. Available under: doi: 10.21873/anticanres.16365BibTex
@article{Zwicker2023Helic-68773, year={2023}, doi={10.21873/anticanres.16365}, title={Helical Tomotherapy of Lymph Node-negative Early-stage Breast Cancer After Breast-conserving Surgery : Long-term Results}, number={5}, volume={43}, issn={0250-7005}, journal={Anticancer Research}, pages={2041--2053}, author={Zwicker, Felix and Klepper, Rudolf and Hauswald, Henrik and Höfel, Sebastian and Raether , Luis and Huber, Peter E. and Debus, Juergen and Schempp, Michael} }
RDF
<rdf:RDF xmlns:dcterms="http://purl.org/dc/terms/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:bibo="http://purl.org/ontology/bibo/" xmlns:dspace="http://digital-repositories.org/ontologies/dspace/0.1.0#" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:void="http://rdfs.org/ns/void#" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" > <rdf:Description rdf:about="https://kops.uni-konstanz.de/server/rdf/resource/123456789/68773"> <dc:language>eng</dc:language> <dc:contributor>Hauswald, Henrik</dc:contributor> <dc:contributor>Schempp, Michael</dc:contributor> <dcterms:isPartOf rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/29"/> <dcterms:available rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2023-12-15T12:26:01Z</dcterms:available> <dcterms:title>Helical Tomotherapy of Lymph Node-negative Early-stage Breast Cancer After Breast-conserving Surgery : Long-term Results</dcterms:title> <dcterms:abstract>Background/Aim: Adjuvant radiotherapy is an integral part of the interdisciplinary curative treatment of breast cancer. We aimed to examine the long-term clinical results of helical tomotherapy in female patients with local restricted, lymph node negative breast cancer after breast-conserving surgery.<br />Patients and Methods: In this single-centre analysis, 219 female patients with early-stage breast cancer (T1/2) and no lymph node metastasis (N0) following breast-conserving surgery and sentinel-node biopsy were treated with adjuvant fractionated whole breast radiation therapy using helical tomotherapy. When boost irradiation was indicated, it was administered sequentially or using the simultaneous-integrated boost technique. Local control (LC), metastasis and survival rates, acute toxicity, late toxicity, and secondary malignancy rates were analysed retrospectively.<br />Results: The mean follow-up time was 71 months. The 5- and 8-year overall survival (OS) rates were 97.7% and 92.1%, respectively. The 5- and 8-year LC rates were 99.5% and 98.2%, while the 5- and 8-year metastasis-free survival (MFS) rates of 97.4% and 94.3%, respectively. Patients with G3 grading or negative hormone receptor status did not show significantly different results. Acute erythema occurred in 79% (grade 0-2) and 21% (grade 3) of the patients. Lymphedema of the ipsilateral arm and pneumonitis occurred in 6.4% and 1.8% of the treated patients. None of the patients developed >grade 3 toxicities during follow-up, while 1.8% developed a secondary malignancy during follow-up.<br />Conclusion: Helical tomotherapy showed excellent long-term results and low toxicity rates. The incidence rates of secondary malignancy were relatively low and correlated with pre-existing data on radiotherapy, suggesting wider implementation of helical tomotherapy in adjuvant radiotherapy for breast cancer patients.</dcterms:abstract> <dc:creator>Raether , Luis</dc:creator> <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2023-12-15T12:26:01Z</dc:date> <foaf:homepage rdf:resource="http://localhost:8080/"/> <dc:creator>Zwicker, Felix</dc:creator> <dc:creator>Debus, Juergen</dc:creator> <dc:contributor>Raether , Luis</dc:contributor> <dc:contributor>Zwicker, Felix</dc:contributor> <dc:contributor>Debus, Juergen</dc:contributor> <dcterms:issued>2023</dcterms:issued> <dc:creator>Schempp, Michael</dc:creator> <dspace:isPartOfCollection rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/29"/> <dc:creator>Hauswald, Henrik</dc:creator> <bibo:uri rdf:resource="https://kops.uni-konstanz.de/handle/123456789/68773"/> <void:sparqlEndpoint rdf:resource="http://localhost/fuseki/dspace/sparql"/> <dc:contributor>Höfel, Sebastian</dc:contributor> <dc:contributor>Klepper, Rudolf</dc:contributor> <dc:contributor>Huber, Peter E.</dc:contributor> <dc:creator>Höfel, Sebastian</dc:creator> <dc:creator>Huber, Peter E.</dc:creator> <dc:creator>Klepper, Rudolf</dc:creator> </rdf:Description> </rdf:RDF>